The “MANIFEST-17K” international study is the first to show important…

---

Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF), according to the largest study of its kind on this new technology, led by the Icahn School of Medicine at Mount Sinai.

The “MANIFEST-17K” international study is the first to show important safety outcomes in a large patient population, including no significant risk of esophageal damage, with PFA is the latest ablation modality approved by the Food and Drug Administration that can be used to restore a regular heartbeat. The findings, published July 8 in Nature Medicine, could lead to more frequent use of PFA instead of conventional therapies to manage AF patients.

Learn all about the difference between regular pneumonia and walking pneumonia in kids and when to take your child to the doctor.

Expression of co-inhibitory receptors or “checkpoint” molecules, such as CTLA-4 and PD-1, on effector T cells is a key mechanism for ensuring immune homeostasis. Dysregulated expression of co-inhibitory receptors on CD4+ T cells promotes autoimmunity while sustained overexpression on CD8+ T cells promotes T cell dysfunction or exhaustion, leading to impaired ability to clear chronic viral infections and cancer. Immune checkpoint blockade (ICB) treatment by blocking CTLA-4 and PD-1 has revolutionized cancer therapies, yet current ICB response rates are still relatively low. This suggests the need to discover novel checkpoint molecules and cell types where checkpoint molecules may be exerting additional or differential effects. We and others have discovered additional checkpoint molecules, including Tim-3, Lag-3, and TIGIT. Using RNA and protein expression profiling at single-cell resolution, we discovered that the checkpoint molecules are expressed as a module that is co-expressed and co-regulated on CD8+ T cells, where they cooperatively induce T cell dysfunction. The same module of checkpoint molecules is also expressed on FoxP3+ Tregs, but their role in regulating immunity and anti-tumor immunity has not been fully appreciated. We have conditionally deleted checkpoint molecules on various cell types including Foxp3+ Tregs and studied their role in regulating autoimmunity, tumor growth, and anti-tumor immunity. Studies with a number of the co-inhibitory molecules on effector T cells, Tregs, and dendritic cells in regulating anti-tumor immunity will be discussed.

Learning Objectives

Stem cells grown in microgravity aboard the International Space Station (ISS) have unique qualities that could one day help accelerate new biotherapies and heal complex disease, two Mayo Clinic researchers say. The research analysis by Fay Abdul Ghani and Abba Zubair, M.D., Ph.D., published in NPJ Microgravity, finds microgravity can strengthen the regenerative potential of cells. Dr. Zubair is a laboratory medicine expert and medical director for the Center for Regenerative Biotherapeutics at Mayo Clinic in Florida. Abdul Ghani is a Mayo Clinic research technologist. Microgravity is weightlessness or near-zero gravity.

“Studying stem cells in space has uncovered cell mechanisms that would otherwise be undetected or unknown within the presence of normal gravity,” says Dr. Zubair. “That discovery indicates a broader scientific value to this research, including potential clinical applications.”

Dr. Zubair has launched stem cell experiments from his lab on three different missions to the ISS. His review paper provides data on the scientific question, “Is space the ideal environment for growing large numbers of stem cells?” Another key concern is whether cells grown in space could maintain their strength and function after splashdown on Earth.

Viruses known as bacteriophages are difficult to study, but they are beginning to give up their secrets.